Where Is Compounded Semaglutide Made? Supply Chain Guide

Quick Answer: Compounded semaglutide typically passes through several hands: an active-ingredient manufacturer, possibly intermediary suppliers, and a licensed pharmacy that prepares the medication for your prescription. Ask your provider and pharmacy which pharmacy compounded it, where that pharmacy is licensed, where the active ingredient was manufactured, and what testing records cover your lot. Compounded semaglutide is not FDA-approved, and a license or registration is not product approval.

Important Disclaimer: Compounded semaglutide is not FDA-approved. FDA does not verify its safety, effectiveness or quality before marketing. This article does not establish equivalence to Ozempic or Wegovy, or the origin of any individual prescription. A license, registration or country-of-origin claim is not product approval. Discuss the exact preparation and approved options with your clinician.

Where does your compounded semaglutide come from? To answer that, identify both the active-ingredient manufacturer and the facility that prepared your medication. This guide explains the records to request and what those records can and cannot establish. It focuses on compounded injectable preparations.

Why the source matters

You are injecting this medication into your body, often weekly, for months. It is completely reasonable to want to know where it came from — not in vague marketing language, but concretely: who made the active ingredient, who turned it into an injectable solution, and what oversight applied along the way.

A U.S. pharmacy address does not identify where the active ingredient was manufactured. Ask for the manufacturer, manufacturing site and lot records associated with your prescription; general statements about an industry or country cannot establish that chain.

Knowing a location does not establish product quality. Review the source, preparation and clinical questions with your pharmacist and prescriber together.

A patient-specific prescription is not the only condition for compounding. The regulatory section below explains why the applicable pathway, copying restrictions and ingredient requirements also matter.

How the compounded semaglutide supply chain works (API → pharmacy → you)

Compounded semaglutide travels through a chain of distinct steps. Understanding the chain is the first step to knowing where any single dose came from.

Step 1: API manufacturing

The active pharmaceutical ingredient (API) is the substance used for the medication’s pharmacologic effect. For a preparation made from bulk semaglutide, ask who manufactured that ingredient and which suppliers handled it before it reached the compounder. Identify these roles separately rather than assuming the dispensing pharmacy made the API.

Step 2: Sourcing and incoming verification

Ask the compounder how it qualifies suppliers, verifies incoming material and links that material to your preparation. A Certificate of Analysis (COA) must be read for its actual lot, tests, methods and results; its title alone does not establish what was tested.

Step 3: Compounding (formulation and sterile preparation)

USP’s sterile-compounding FAQ explains that Chapter <797> addresses sterile preparations. Requirements differ by preparation category and conditions; a single cleanroom description does not establish compliance. Ask which standards apply, what ingredients were used and how the process was documented.

Step 4: Quality control

Ask which quality-control tests apply to the preparation and which records support its release. USP’s FAQ distinguishes testing requirements by preparation category, components and beyond-use date. Testing samples does not guarantee sterility of every unit, and an API COA is not a finished-product test.

Step 5: Dispensing and shipping to you

Obtain the medication through your prescriber and dispensing pharmacy. FDA advises patients not to use injectable GLP-1 medication that arrives warm or inadequately refrigerated. Contact the pharmacy about the condition of the delivery and the preparation’s storage and discard instructions.

Stage	Who is responsible	What to verify
API manufacturing	Identified ingredient manufacturer	Site, lot and records linking the ingredient to the preparation
Sourcing	Compounding pharmacy	Supplier vetting; incoming lot testing
Compounding	Identified compounder	Regulatory pathway, applicable standards and preparation records
Quality control	Pharmacy / contracted lab	Applicable tests, samples, methods and results
Dispensing	Pharmacy + prescriber	Valid prescription; cold-chain shipping

Ask two separate questions: where was the API manufactured, and where was it made into the finished preparation? The dispensing label alone may not answer both.

The API question — where the active ingredient comes from and why source matters

Distinguish general industry data from evidence about your prescription.

FDA’s October 2019 supply-chain testimony describes API facilities in the United States, China and other countries. It also explains that facility counts could not determine production volumes or which source supplied a finished product at a given time. This is historical industry context, not current semaglutide sourcing data.

This article has no lot-specific evidence establishing the country of origin of your semaglutide. Request that evidence from the dispensing pharmacy. A country name alone does not establish that the ingredient or finished preparation meets applicable quality requirements.

What “FDA-registered API source” does and does not mean

Ask which manufacturer and establishment record support an “FDA-registered” claim. FDA explains that registration and drug listing do not mean the product is approved or that FDA has verified the submitted information.

Registration, a pharmacy license and an ingredient COA answer different questions. None independently establishes the quality of a finished compounded medication. Ask the pharmacist to connect the supplier records to the actual preparation and its release records.

What the records should clarify

• Identity: Which methods and results identify the ingredient and its chemical form?
• Purity: Which impurities were assessed, with what limits and results?
• Potency: Does the report concern the ingredient or the concentration of the finished preparation?
• Traceability: How do the manufacturer, supplier and preparation records connect to your lot?

FDA warns against unapproved GLP-1 products falsely labeled for research but sold to consumers for human use. Their quality is unknown and they may be harmful. Do not buy such material for treatment.

Semaglutide salt forms vs base — what the FDA flagged and what to ask

The chemical form is another question to verify in the ingredient records.

FDA’s unapproved GLP-1 warning identifies semaglutide sodium and semaglutide acetate as different active ingredients from those in approved products. FDA says it lacks information about whether their chemical and pharmacologic properties are the same and is not aware of a lawful basis for using them in compounding.

Ask the pharmacist to identify the ingredient and explain the records supporting that identification. Using semaglutide base does not establish that a compounded finished product is equivalent to an approved medication.

Questions worth asking about chemical form

• “Is this preparation made with semaglutide base, or with a salt form such as sodium or acetate?”
• “Can you provide a Certificate of Analysis that identifies the chemical form and the API source?”
• “How do you verify the identity of the API on incoming lots?“

503A compounding pharmacies — who makes your medication and what oversight applies

FDA describes multiple compounding settings. State boards generally have primary oversight of state-licensed pharmacies operating under 503A; FDA also inspects them. Federal law also addresses physicians and federal facilities. Registered 503B outsourcing facilities have primary FDA oversight and remain subject to current good manufacturing practice requirements. These pathways do not make compounded products FDA-approved.

Patient-specific prescriptions and copying restrictions

FDA’s April 1, 2026 update explains that 503A restricts compounding essentially copies of commercially available products regularly or in inordinate amounts. A prescriber-determined and documented change producing a significant difference for an identified patient can fall outside that copying definition. Other conditions still apply; a prescription alone is insufficient.

503B has separate bulk-ingredient restrictions. In that dated update, FDA states that semaglutide is on neither the shortage list nor the 503B bulks list. Describing 503B does not establish permission to compound semaglutide from bulk under that pathway. Ask the prescriber and pharmacist to identify the requirements for your exact preparation.

How to find out where YOUR medication comes from

Use the following questions to request and check records. This article has not verified a particular pharmacy, supplier or lot.

Questions to ask your provider and pharmacy

• “Which licensed pharmacy compounds my semaglutide, and in which state is it licensed?”
• “Which regulatory pathway and requirements apply to this preparation?”
• “Where is the semaglutide API manufactured, and is the supplier FDA-registered?”
• “Is the preparation made with the base form of semaglutide?”
• “Can you provide a Certificate of Analysis for my lot?”
• “Do you perform sterility, endotoxin, and potency testing?”
• “What is the beyond-use date, and how should I store and handle it?”

How to verify the answers

• Certificate of Analysis (COA): Identify the material, lot, tests and results covered. Ask whether it concerns the ingredient or the finished preparation and how the pharmacy used it in its quality assessment.
• State board of pharmacy: Use FDA’s state license-lookup links to check the dispensing pharmacy. Contact the board about an unclear listing or disciplinary records.
• Accreditation: If a pharmacy claims accreditation, ask which organization and program issued it, then check that organization’s directory. Accreditation and state licensure are different checks.
• FDA records: Review compounding inspections, recalls and other actions. Match the facility identity and dates; an absence of results is not a quality endorsement.

Sources to avoid entirely

• ❌ Sellers that are not licensed U.S. pharmacies and have no verifiable oversight
• ❌ “Research-only” or non-pharmaceutical-grade material sold for human use
• ❌ Sources that do not require a valid prescription from a licensed provider
• ❌ Sellers that cannot identify the medication’s source or explain its quality records
• ❌ Sources that make guaranteed-outcome promises or skip cold-chain shipping

How Boca Health approaches provenance

Given everything above, here is how Boca Health approaches the question of where your medication comes from. We are describing our process, not making safety guarantees.

Boca works with WellSync and other state-licensed 503A compounding pharmacies in the WellSync network. The pharmacies in this network prepare semaglutide for an individual patient pursuant to a valid prescription, under USP <795>/<797> standards, and source semaglutide API from suppliers that register with the FDA and provide a Certificate of Analysis. A licensed clinician determines whether a compounded preparation is appropriate for a patient’s specific clinical situation before anything is prescribed.

We want to be measured and honest about what this does and does not mean:

• Vetting suppliers, using licensed U.S. pharmacies, and reviewing documentation can reduce certain risks — particularly the risks tied to unverified, untraceable sources. It does not eliminate risk, and we do not claim it does.
• Compounded semaglutide is not FDA-approved and has not been shown to be equivalent or interchangeable with Ozempic or Wegovy. The fact that a pharmacy is U.S.-based and state-licensed does not change that.
• A facility’s registration or license is not FDA approval of the medication.

What we will commit to is transparency: telling you plainly how your medication is sourced and prepared, and supporting your right to ask the questions in the section above. If you want to see how that process works in practice, you can explore Boca’s weight-loss program and discuss it with a licensed provider. For broader background, our compounded semaglutide safety guide and our explainer on whether compounded semaglutide is FDA-approved go deeper on the regulatory picture.

Boxed Warning: Risk of Thyroid C-Cell Tumors

Wegovy labeling warns of thyroid C-cell tumors in rodents; whether this occurs in humans is unknown. Its contraindications include personal or family medullary thyroid carcinoma, MEN 2 and prior serious hypersensitivity to semaglutide or its ingredients. Tell your clinician about these conditions before treatment. This approved-product label does not establish the safety or equivalence of a compounded preparation; the exact product requires clinical assessment.

Frequently Asked Questions

Where do compounding pharmacies get the API for semaglutide?

Ask the pharmacy to identify the API manufacturer, any intermediary suppliers and the lot records associated with your preparation. A registration record and an ingredient COA do not by themselves verify the finished product’s quality.

Is compounded semaglutide made in China?

This article cannot identify the country of origin of your prescription. Request the manufacturer, site and lot records from the pharmacy. General data about overseas pharmaceutical facilities cannot establish where a particular semaglutide preparation’s ingredient was made.

What is the difference between semaglutide salt and base?

FDA identifies semaglutide sodium and acetate as different active ingredients from those in approved products and says it is not aware of a lawful basis for using them in compounding. Ask the pharmacist to identify the chemical form and supporting records. Using base semaglutide does not establish finished-product equivalence.

How do I find out where my compounded semaglutide is made?

Ask who manufactured the ingredient, who compounded the medication and which records connect those steps to your prescription. Verify the dispensing pharmacy’s license with your state board and ask the pharmacist to explain the applicable regulatory pathway and quality records.

Is US-compounded semaglutide safer than imported?

Country of origin alone does not establish comparative safety. This article has not compared specific products or verified their manufacturers. A license, registration or COA does not establish FDA approval or equivalence to Ozempic or Wegovy; review the exact preparation with your clinician and pharmacist.

Related Articles

• Is Compounded Semaglutide Safe? What You Should Know
• Is Compounded Semaglutide FDA-Approved?
• The Complete Guide to Semaglutide
• Microdosing Semaglutide: What to Know